Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
about
Clinical management of localized colon cancer with capecitabineSingle Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and IIImplications of mismatch repair-deficient status on management of early stage colorectal cancerAdjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysisTreatment of colorectal cancer in the elderlyManagement of colorectal cancerManagement of locally advanced and metastatic colon cancer in elderly patientsTNM staging of colorectal cancer should be reconsidered by T stage weightingThe IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 montClausenidin induces caspase-dependent apoptosis in colon cancerImpact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised coEffect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancerAdjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review.Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapyPharmaco-economic analysis of adjuvant chemotherapy for stage II and III colorectal cancerAdjuvant chemotherapyAssociation between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.Colorectal cancer: from prevention to personalized medicine.Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer.The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and reviewPredicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradationThe effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas.Factors associated with delayed time to adjuvant chemotherapy in stage iii colon cancerLong-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).Oxaliplatin-based adjuvant chemotherapy without radiotherapy can improve the survival of locally-advanced rectal cancerTreatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer?Indian Council of Medical Research consensus document for the management of colorectal cancer.Adjuvant therapy for resected high-risk colon cancer: Current standards and controversiesPrognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer
P2860
Q24611758-B4EBC5EF-E76B-4EEA-99F1-768563398DF6Q26765344-BC9FE58B-310D-49D1-AA4D-7F089E1FF917Q26772272-86F8EB1F-B8BD-4B7D-A34E-514AF570A0ABQ26774704-C810C934-93C5-4150-B864-22E37BC2DD4CQ26781457-EB669CE9-46AD-4FC3-A38F-DE1305C56880Q26823550-0B8ADB79-275A-4CB7-A36D-607BD52537EFQ27026129-BA6ED77D-DA4F-4CB6-AECE-9E9FCF6C35F1Q28658050-58541F9A-E89E-4793-9AB3-9AF2AEC24909Q28681140-C3018377-3E2C-4236-BEE5-FFD3ED0135B1Q28828420-710A0645-5F54-4183-B223-954F75798FA6Q30315675-29B3FB67-4773-4CC7-8F8A-F89785D41267Q30316930-8A9EA062-56BD-4C9B-846C-FC943BEA4B57Q30418160-F4D7F42D-570F-4DE6-9B05-3C3C2EF8B7A4Q30422446-9B8F9904-BA46-473E-BFD6-E86120871500Q30625567-541DF71E-CDED-471E-8DF6-7FA615406EA7Q30884763-BA079084-1A63-4656-8C98-13C33DEE6A17Q33405177-8847263A-0137-43A0-8ABB-91207D7C069CQ33411783-4B4B3497-E412-4143-B9ED-BF5205B438F2Q33426784-C776F65D-7E78-49C5-B835-75EF93888D87Q33430668-FBF57D2A-213C-4823-95E1-2CDE68DFF164Q33558347-E15D6119-D0F4-4F13-B379-F902CB3B87DBQ33685203-B95A3BE4-08D3-4715-AD17-501631813E7FQ33698724-E8559E82-E05A-493C-B327-73598E8CC4D9Q33727059-74EBA0C0-D344-477F-820D-39BB6E2489DBQ33729819-2D570DC3-E84D-45D3-B976-B249A3406BECQ33735234-2A50D66E-0B5B-4A3D-9DA3-D17C58856291Q33761570-77493528-FF01-4658-9D5E-451F711716B8Q33761655-F48565E9-90EE-43EF-A5BE-4099717C7B12Q33826355-BFBA03C4-DE77-48B0-A144-EE4A43ED135EQ33851067-66DA54EB-32D1-4E8C-AE03-A85C9CA98916Q33895624-52BF3CC1-3694-4414-B8FC-2519103EE8A5Q33982660-B328EFAD-1ED0-414A-9DBE-85B7B89853F8Q34039871-62AC5F6E-8D21-40B7-82E1-2434D4608E3DQ34083135-136CDE23-78A4-4D56-9B82-E8D518C84B06Q34226859-7BF769B8-AE31-4C51-8925-CB4845670EAEQ34294365-888A1985-029D-49AB-BF79-359C3E53A7FDQ34357769-790D08CE-7A97-47CF-BF24-981479EA8203Q34368271-18EDFAE7-692D-4858-825A-325AF6883FEBQ34368278-27E5E0D2-096A-4013-AED4-4764CE54A4C4Q34472453-E6A910A2-A81C-4EA8-B83D-43B82BF03CA5
P2860
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Capecitabine plus oxaliplatin ...... py for stage III colon cancer.
@ast
Capecitabine plus oxaliplatin ...... py for stage III colon cancer.
@en
type
label
Capecitabine plus oxaliplatin ...... py for stage III colon cancer.
@ast
Capecitabine plus oxaliplatin ...... py for stage III colon cancer.
@en
prefLabel
Capecitabine plus oxaliplatin ...... py for stage III colon cancer.
@ast
Capecitabine plus oxaliplatin ...... py for stage III colon cancer.
@en
P2093
P50
P356
P1476
Capecitabine plus oxaliplatin ...... apy for stage III colon cancer
@en
P2093
Daniel G Haller
Eric Van Cutsem
Frank Gilberg
Hans-Joachim Schmoll
Jean Maroun
Karen Rittweger
P304
P356
10.1200/JCO.2010.33.6297
P407
P577
2011-03-07T00:00:00Z